BMS and Ono sue Amgen as FDA weighs Opdivo biosimilar on September 16, 2026 ABP Actin-Binding Protein Amgen Biosimilars Delaware Myers Squibb nivolumab Opdivo patent litigation United States Food and Drug Administration +